Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
CMPX Quote, Financials, Valuation and Earnings
Last price:
$5.15
Seasonality move
:
-8.55%
Day range:
$5.03 - $5.20
52-week range:
$1.33 - $5.86
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.36x
Volume:
631K
Avg. volume:
2M
1-year change:
242.67%
Market cap:
$914.2M
Revenue:
$850K
EPS (TTM):
-$0.46
Analysts' Opinion
-
Consensus RatingCompass Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.62, Compass Therapeutics, Inc. has an estimated upside of 145.44% from its current price of $5.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $5.14.
Fair Value
-
According to the consensus of 11 analysts, Compass Therapeutics, Inc. has 145.44% upside to fair value with a price target of $12.62 per share.
CMPX vs. S&P 500
-
Over the past 5 trading days, Compass Therapeutics, Inc. has overperformed the S&P 500 by 2.17% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Compass Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Compass Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Compass Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Compass Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Compass Therapeutics, Inc. reported earnings per share of -$0.08.
Enterprise value:
704.2M
EV / Invested capital:
3.21x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.39x
EV / Free cash flow:
-15.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.5M
Return On Assets:
-42.79%
Net Income Margin (TTM):
--
Return On Equity:
-48.62%
Return On Invested Capital:
-45.93%
Operating Margin:
-1770%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $850K | -- | -- | -- | |
| Gross Profit | -$1.9M | -$1M | -$1.5M | -$465K | -$371K | |
| Operating Income | -$47.9M | -$55.4M | -$71.4M | -$12.2M | -$15.8M | |
| EBITDA | -$46M | -$53.6M | -$70M | -$11.8M | -$15.4M | |
| Diluted EPS | -$0.33 | -$0.36 | -$0.46 | -$0.08 | -$0.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $28.6M | $122.6M | $166.6M | $141.1M | $221.1M | |
| Total Assets | $34.9M | $127.8M | $170M | $149.2M | $231.3M | |
| Current Liabilities | $7.7M | $9.6M | $9.1M | $4.4M | $12.4M | |
| Total Liabilities | $11M | $11.7M | $10M | $10.8M | $21.6M | |
| Total Equity | $23.9M | $116.1M | $160M | $138.4M | $209.6M | |
| Total Debt | $7.1M | $2.1M | $869K | $6.3M | $9.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$38.9M | -$48M | -$45.1M | -$11.1M | -$10.8M | |
| Cash From Investing | -$26M | $37.7M | -$74.6M | $29M | -$95.2M | |
| Cash From Financing | $78.8M | $17.3M | $128.5M | -$2K | $129.4M | |
| Free Cash Flow | -$39M | -$48.1M | -$45.1M | -$11.1M | -$10.9M | |
CMPX
Sector
Market Cap
$914.2M
$28M
Price % of 52-Week High
87.71%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-21.1%
-1.54%
1-Year Price Total Return
242.67%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.09
200-day SMA
Buy
Level
$3.17
Bollinger Bands (100)
Buy
Level
3.22 - 4.86
Chaikin Money Flow
Sell
Level
-25.1M
20-day SMA
Sell
Level
$5.26
Relative Strength Index (RSI14)
Buy
Level
53.13
ADX Line
Buy
Level
22.17
Williams %R
Neutral
Level
-66.4865
50-day SMA
Buy
Level
$4.70
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
56.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.0015)
Buy
CA Score
(Annual)
Level (-0.2485)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.301)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, CMPX has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CMPX average analyst price target in the past 3 months is $12.62.
-
Where Will Compass Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Compass Therapeutics, Inc. share price will rise to $12.62 per share over the next 12 months.
-
What Do Analysts Say About Compass Therapeutics, Inc.?
Analysts are divided on their view about Compass Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Compass Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Compass Therapeutics, Inc.'s Price Target?
The price target for Compass Therapeutics, Inc. over the next 1-year time period is forecast to be $12.62 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CMPX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Compass Therapeutics, Inc. is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CMPX?
You can purchase shares of Compass Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Compass Therapeutics, Inc. shares.
-
What Is The Compass Therapeutics, Inc. Share Price Today?
Compass Therapeutics, Inc. was last trading at $5.15 per share. This represents the most recent stock quote for Compass Therapeutics, Inc.. Yesterday, Compass Therapeutics, Inc. closed at $5.14 per share.
-
How To Buy Compass Therapeutics, Inc. Stock Online?
In order to purchase Compass Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CMPX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CMPX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.39x
-0.01x
P/B ratio
4.36x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
CMPX
Sector
Revenue growth
-100%
4.62%
Earnings growth
-10.89%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.13
-$0.21
Profitability
CMPX
Sector
Profitability FY 2024
-$903K
$3.5M
Return on invested capital
-45.93%
-31.77%
Return on assets
-42.79%
-27.96%
Return on equity
-48.62%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
CMPX
Sector
Total cash
$219.9M
$26.3M
Short term investments
$83.2M
$25.7M
Total assets
$140.4M
$78M
Long term debt
$9.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
